91449-79-5CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1OHTTJABKRGRZYRN-UHFFFAOYSA-Nenoxaparin fragment has been reported in Hydropuntia edulis, Sargassum myriocystum, and other organisms with data available.
91449-79-5Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
As an anticoagulant, the main risk of LMWH is bleeding. Less common adverse effects include heparin-induced thrombocytopenia, osteoporosis, spontaneous fractures, hypoaldosteronism, and hypersensitivity reactions. In assessing the need for anticoagulant medication, clinicians must consider the risks posed by bleeding versus the risks of clotting.
BeschreibungEnoxaparin is a low molecular weight heparin fraction obtained by controlled depolymerization of pig heparin. As an anticoagulant it is reportedly useful in the treatment of venous thromboembolism, and the prevention of coagulation in the extracorporeal circulation during hemodialysis.
Wird geladen…
Wird geladen…
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…